Company news
Harrow, Inc. news in 2024
Harrow, Inc.'s news releases, calls and decks from 2024, newest first.
Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.
November 20, 2024
Harrow Announces Participation in Upcoming Investor Conferences
November 14, 2024
Harrow Launches Access and Affordability Program with Price Reductions for Branded Products
November 12, 2024
Harrow Announces Third Quarter 2024 Financial Results
November 12, 2024
Harrow Announces Market Access Wins for VEVYE®
November 11, 2024
Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow’s Branded Eyecare Products
November 6, 2024
Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024
October 30, 2024
Harrow Relaunches TRIESENCE®
October 2, 2024
Harrow Announces Nashville Expansion
September 24, 2024
Harrow to Present at Three Investor Conferences in September in New York
September 2, 2024
Harrow Announces Second Quarter 2024 Financial Results
August 6, 2024
Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024
July 24, 2024
Harrow to Attend 2024 ASRS Annual Meeting
July 11, 2024
Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow Products
July 8, 2024
Harrow Provides TRIESENCE® Relaunch Update
June 19, 2024
Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study
June 4, 2024
Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial
May 12, 2024
Harrow Announces First Quarter 2024 Financial Results
May 12, 2024
Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
April 24, 2024
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
March 18, 2024
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
March 4, 2024
Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
February 14, 2024
Harrow Announces New Appointments to its Board of Directors
January 28, 2024
Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease
January 10, 2024
Melt Pharmaceuticals Provides Corporate Update
January 2, 2024
Harrow Partners with Leading Healthcare Market Access Technology Platforms
January 2, 2024
Calls in 2024
Decks in 2024
- H.C. Wainwright 26th Annual Global Investment Conference 2024
Conference · 14 slides · Sep 9, 2024
- Investor Presentation (March 2024)
Investor deck · 24 slides · Mar 19, 2024